FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

D Cejka; Claudia Kuntner; M Preusser; M Fritzer-Szekeres; B Fueger; S Strommer; J Werzowa; T Fuererder; Thomas Wanek; M Zsebedics; M Müller; Oliver Langer; V Wacheck

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

D Cejka, Claudia Kuntner, M Preusser, M Fritzer-Szekeres, B Fueger, S Strommer, J Werzowa, T Fuererder, Thomas Wanek, M Zsebedics, M Müller, Oliver Langer, V Wacheck

Radiation, Safety and Applications

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1739-1745
Number of pages	7
Journal	British Journal of Cancer
Volume	100
Issue number	11
Publication status	Published - 2009

Research Field

Former Research Field - Health and Bioresources

Cite this

@article{1a124f6a458b476bb51f1f29e43848e8,

title = "FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo",

author = "D Cejka and Claudia Kuntner and M Preusser and M Fritzer-Szekeres and B Fueger and S Strommer and J Werzowa and T Fuererder and Thomas Wanek and M Zsebedics and M M{\"u}ller and Oliver Langer and V Wacheck",

year = "2009",

language = "English",

volume = "100",

pages = "1739--1745",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

AU - Cejka, D

AU - Kuntner, Claudia

AU - Preusser, M

AU - Fritzer-Szekeres, M

AU - Fueger, B

AU - Strommer, S

AU - Werzowa, J

AU - Fuererder, T

AU - Wanek, Thomas

AU - Zsebedics, M

AU - Müller, M

AU - Langer, Oliver

AU - Wacheck, V

PY - 2009

Y1 - 2009

M3 - Article

SN - 0007-0920

VL - 100

SP - 1739

EP - 1745

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 11

ER -